GeneLeap Biotech is a global company in the Luye Life sciences portfolio of companies,a leader in China and a new entrant in the US. Our goal is to deliver a best-in-class portfolio of completely novel RNA&mRNA based drugs and vaccines.
Leveraging recent breakthroughs in mRNA therapy
GeneLeap Biotech leverages recent breakthroughs in nucleic acid technologies to deliver solutions for infectious diseases and cancer. Targeting patient populations with urgent and unmet medical needs, we innovate in the precision medicine space to bring about positive impact to difficult prognoses.
Dr. Langer’s pioneering work in the study and development of polymers to deliver drugs, particularly macromolecules, has lead to countless breakthroughs in the filed of biotechnology, and has led to the advancement of countless therapeutics.
Dr. Langer will advise on the development of delivery platforms for non-messenger RNA therapeutic approaches.
Dr. D. Weissman is a Professor in the Department of Medicine and Director of Vaccine Research in the Infectious Diseases Division at the Perelman School of Medicine at the University of Pennsylvania. Dr. D. Weissman and his collaborator, Dr. KatalinKarikó discovered a therapeutic technology based on the modification of mRNA.
His work helped enable development of effective mRNA vaccines, the best known of which are those for COVID-19 produced by BioNTech/Pfizer and Moderna. Upon this, he received Lasker-DeBakey Clinical Medical Research Award.